Collectively, these findings identify CGR11 as a novel regulator of the PI3K/AKT-autophagy axis and suggest that targeting CGR11 may provide a promising therapeutic strategy and prognostic biomarker for HCC. Here, AKT1 is linked to hepatocellular carcinoma.